Skip to main content

Advertisement

SpringerLink
Log in

Human Papillomavirus-Associated Oropharynx Cancer (HPV-OPC): Treatment Options

  • Head and Neck Cancer (J-P Machiels, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Human papillomavirus-associated oropharynx cancer (HPV-OPC) is growing in incidence and has distinct clinical, pathologic, molecular, and epidemiologic features. However, the management of HPV-OPC does not presently differ from HPV-negative OPC based on the current evidence and requires complex multidisciplinary approaches. The superior prognosis of HPV-OPC and the toxicities of current multimodality treatment in a young population serve as the impetus to evaluate de-intensification treatment regimens aimed at reducing toxicity while maintaining therapeutic efficacy. Clinical trials are underway to evaluate reduced doses of radiation or less toxic systemic therapy regimens in HPV-OPC. Minimally invasive surgical approaches in the HPV-OPC population with early tumor stage also are being investigated. De-intensification strategies should only be employed in the context of clinical trials, and HPV-OPC patients should be offered clinical trials’ participation. Appropriate patient selection is critical to the development of de-intensification regimens, and this requires greater understanding of risk factors within the HPV-OPC population, HPV-OPC biology, and how HPV modulates response to specific therapies. Smoking history and bulky nodal disease have been shown to impact negatively the favorable prognosis of HPV association. Validated biomarkers within the HPV-OPC population are lacking, although alterations in the PI3K pathway and markers of immune response may emerge as important considerations in the future. Novel therapeutic strategies are desperately needed particularly for HPV-OPC patients who fail definitive therapy, and select patients with recurrent or metastatic disease may benefit from aggressive approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.

    Article  PubMed  CAS  Google Scholar 

  2. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709–20.

    Article  PubMed  CAS  Google Scholar 

  3. Gillison ML, D’Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100:407–20.

    Article  PubMed  Google Scholar 

  4. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294–301.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35. Key retrospective study demonstrating the prognostic value of HPV in patients with oropharyngeal cancer treated with chemoradiation.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Lassen P, Eriksen JG, Krogdahl A, et al. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol. 2011;100:49–55.

    Article  PubMed  CAS  Google Scholar 

  7. Posner MR, Lorch JH, Goloubeva O, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol. 2011;22:1071–7.

    Article  PubMed  CAS  Google Scholar 

  8. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol. 2010;28:4142–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Chaturvedi AK, Engels EA, Anderson WF, et al. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26:612–9.

    Article  PubMed  Google Scholar 

  10. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013;31:4550–9.

    Article  PubMed  Google Scholar 

  11. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA. 2012;307:693–703.

    Article  PubMed  CAS  Google Scholar 

  12. Mehanna H, Beech T, Nicholson T, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer–systematic review and meta-analysis of trends by time and region. Head Neck. 2013;35:747–55.

    Article  PubMed  Google Scholar 

  13. D’Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356:1944–56.

    Article  PubMed  Google Scholar 

  14. D’Souza G, Gross ND, Pai SI, et al. Oral Human Papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. J Clin Oncol; 2014

  15. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11:9–22.

    Article  PubMed  CAS  Google Scholar 

  16. Smeets SJ, van der Plas M, Schaaij-Visser TB, et al. Immortalization of oral keratinocytes by functional inactivation of the p53 and pRb pathways. Int J Cancer. 2011;128:1596–605.

    Article  PubMed  CAS  Google Scholar 

  17. Rampias T, Sasaki C, Weinberger P, et al. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst. 2009;101:412–23.

    Article  PubMed  CAS  Google Scholar 

  18. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333:1157–60. Whole exome sequencing study which identified many genes not previously implicated in HNSCC including genes that regulate squamous differentiation.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  19. Wilting SM, Smeets SJ, Snijders PJ, et al. Genomic profiling identifies common HPV-associated chromosomal alterations in squamous cell carcinomas of cervix and head and neck. BMC Med Genomics. 2009;2:32.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Smeets SJ, Braakhuis BJ, Abbas S, et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene. 2006;25:2558–64.

    Article  PubMed  CAS  Google Scholar 

  21. Slebos RJ, Jehmlich N, Brown B, et al. Proteomic analysis of oropharyngeal carcinomas reveals novel HPV-associated biological pathways. Int J Cancer. 2013;132:568–79.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  22. Sewell A, Brown B, Biktasova A, et al. Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer. Clin Cancer Res. 2014;20:2300–11.

    Article  PubMed  CAS  Google Scholar 

  23. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008;26:3128–37.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Young RJ, Rischin D, Fisher R, et al. Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2011;20:1230–7.

    Article  PubMed  CAS  Google Scholar 

  25. Pai SI, Westra WH. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol. 2009;4:49–70.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  26. Goldenberg D, Begum S, Westra WH, et al. Cystic lymph node metastasis in patients with head and neck cancer: an HPV-associated phenomenon. Head Neck. 2008;30:898–903.

    Article  PubMed  Google Scholar 

  27. Huang SH, Perez-Ordonez B, Liu FF, et al. Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys. 2012;82:276–83.

    Article  PubMed  Google Scholar 

  28. Schache AG, Liloglou T, Risk JM, et al. Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res. 2011;17:6262–71.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  29. Adelstein DJ, Ridge JA, Gillison ML, et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck. 2009;31:1393–422.

    Article  PubMed  Google Scholar 

  30. Huang CC, Qiu JT, Kashima ML, et al. Generation of type-specific probes for the detection of single-copy human papillomavirus by a novel in situ hybridization method. Mod Pathol. 1998;11:971–7.

    PubMed  CAS  Google Scholar 

  31. Klussmann JP, Gultekin E, Weissenborn SJ, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol. 2003;162:747–53.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  32. Shi W, Kato H, Perez-Ordonez B, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol. 2009;27:6213–21.

    Article  PubMed  Google Scholar 

  33. Fakhry C, Zhang Q, Nguyen-Tan PF, et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol; 2014.

  34. Haughey BH, Hinni ML, Salassa JR, et al. Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck. 2011;33:1683–94.

    Article  PubMed  Google Scholar 

  35. Moore EJ, Olsen SM, Laborde RR, et al. Long-term functional and oncologic results of transoral robotic surgery for oropharyngeal squamous cell carcinoma. Mayo Clin Proc. 2012;87:219–25.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Nichols AC, Yoo J, Hammond JA, et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR)--study protocol for a randomized phase II trial. BMC Cancer. 2013;13:133.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368:843–54.

    Article  PubMed  Google Scholar 

  38. Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011;12:127–36.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Hunter KU, Schipper M, Feng FY, et al. Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes. Int J Radiat Oncol Biol Phys. 2013;85:935–40.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48:7–16.

    Article  PubMed  CAS  Google Scholar 

  41. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHAN CA 6 and 7 randomised controlled trial. Lancet. 2003;362:933–40.

    Article  PubMed  Google Scholar 

  42. Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol. 2012;13:145–53.

    Article  PubMed  Google Scholar 

  43. Beitler JJ, Zhang Q, Fu KK, et al. Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2014;89:13–20. Largest prospective trial to compare altered fractionation with conventional fractionation, demonstrating hyperfractionated and accelerated radiation with concomitant boost decreased locoregional failure.

    Article  PubMed  Google Scholar 

  44. Bensadoun RJ, Benezery K, Dassonville O, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys. 2006;64:983–94.

    Article  PubMed  CAS  Google Scholar 

  45. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1798–804.

    Article  PubMed  CAS  Google Scholar 

  46. Budach V, Stuschke M, Budach W, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol. 2005;23:1125–35.

    Article  PubMed  CAS  Google Scholar 

  47. Pignon JP, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4–14.

    Article  PubMed  Google Scholar 

  48. Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011;100:33–40.

    Article  PubMed  Google Scholar 

  49. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21–8.

    Article  PubMed  CAS  Google Scholar 

  50. Rosenthal DI, Harari PM, Giralt J, et al. Impact of p16 status on the results of the phase III cetuximab (cet)/radiotherapy (RT). J Clin Oncol. 2014;32. 5s:abstr 6001.

  51. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705–15. Landmark phase III trial demonstrating the TPF induction chemotherapy as an effective and superior induction regimen.

    Article  PubMed  CAS  Google Scholar 

  52. Haddad R, O’Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013;14:257–64. Landmark phase III trial designed to compare sequential chemoradiotherapy utilizing TPF induction chemotherapy versus concurrent chemoradiation.

    Article  PubMed  CAS  Google Scholar 

  53. Deeken JF, Newkirk K, Harter KW, et al. Effect of multimodality treatment on overall survival for patients with metastatic or recurrent HPV-positive head and neck squamous cell carcinoma. Head Neck; 2014

  54. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27. Landmark phase III trial establishing survival benefit with the addition of cetuximab to chemotherapy in recurrent/metastatic head and neck cancer.

    Article  PubMed  CAS  Google Scholar 

  55. Vermorken JB, Stohlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013;14:697–710.

    Article  PubMed  CAS  Google Scholar 

  56. Seiwert TY, Fayette J, Cupissol DA, et al. A randomized, open-label, phase II study of afatinib (BIBW 2992) versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck cancer: Final data, Multidisciplinary Head and Neck Cancer Symposium; 2012

  57. Chau NG, Perez-Ordonez B, Zhang K, et al. The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck Oncol. 2011;3:11.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  58. Psyrri A, Licitra L, Blas BD, et al. Safety and efficacy of cisplatin plus 5-FU and cetuximab in HPV-positive and HPV-negative recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCH N): analysis of the phase III EXTREME trial. Ann Oncol. 2012;23 Suppl 9:10180.

    Google Scholar 

  59. Silander E, Nyman J, Bove M, et al. Impact of prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients with head and neck cancer: a randomized study. Head Neck. 2012;34:1–9.

    Article  PubMed  Google Scholar 

  60. Chen AM, Chen LM, Vaughan A, et al. Tobacco smoking during radiation therapy for head-and-neck cancer is associated with unfavorable outcome. Int J Radiat Oncol Biol Phys. 2011;79:414–9.

    Article  PubMed  Google Scholar 

  61. Carnaby-Mann G, Crary MA, Schmalfuss I, et al. ‘Pharyngocise’: randomized controlled trial of preventative exercises to maintain muscle structure and swallowing function during head-and-neck chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012;83:210–9.

    Article  PubMed  Google Scholar 

  62. Gillison ML, Zhang Q, Jordan R, et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol. 2012;30:2102–11.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  63. O’Sullivan B, Huang SH, Siu LL, et al. De-intensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol. 2013;31:543–50. Large retrospective study evaluating OPC patients treated with definitive radiation based therapy to define candidate subgroups for deintensification according to lowest risk of developing distant metastases.

    Article  PubMed  Google Scholar 

  64. Gupta AK, Lee JH, Wilke WW, et al. Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT. Int J Radiat Oncol Biol Phys. 2009;74:928–33.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Kimple RJ, Smith MA, Blitzer GC, et al. Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res. 2013;73:4791–800.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  66. Rieckmann T, Tribius S, Grob TJ, et al. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. Radiother Oncol. 2013;107:242–6.

    Article  PubMed  CAS  Google Scholar 

  67. Cmelak A, Li S, Marur S, et al. E1308: Reduced-dose IMRT in HPV-associated resectable oropharyngeal squamous cell carcinomas after complete clinical response to induction chemotherapy. J Clin Oncol. 2014;32. 5s:LBA 6006.

  68. Lui VW, Hedberg ML, Li H, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013;3:761–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  69. Young NR, Liu J, Pierce C, et al. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol Oncol. 2013;7:359–68.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  70. Byers LA, Diao L, Ng PK, et al. Proteomic profiling of HPV-positive head and neck cancer to identify new candidates for targeted therapy. J Clin Oncol. 2014;32. 5s:abstr 6030.

  71. Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73:1733–41.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  72. Ward MJ, Thirdborough SM, Mellows T, et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br J Cancer. 2014;110:489–500.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  73. Badoual C, Hans S, Merillon N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013;73:128–38.

    Article  PubMed  CAS  Google Scholar 

  74. Seiwert TY, Burtness B, Weiss J, et al. A phase Ib study of MK-3475 in patients with HPV-associated and non-HPV associated head and neck cancer. J Clin Oncol. 2014;32. 5s:abstr 6011.

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Nicole G. Chau, Guilherme Rabinowits, and Robert I. Haddad declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA

    Nicole G. Chau MD, Guilherme Rabinowits MD & Robert I. Haddad MD

Authors
  1. Nicole G. Chau MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guilherme Rabinowits MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert I. Haddad MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicole G. Chau MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chau, N.G., Rabinowits, G. & Haddad, R.I. Human Papillomavirus-Associated Oropharynx Cancer (HPV-OPC): Treatment Options. Curr. Treat. Options in Oncol. 15, 595–610 (2014). https://doi.org/10.1007/s11864-014-0309-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-014-0309-1

Keywords

Search

Navigation